Somatic Nrf2 gain-of-function and Keap1 loss-of-function mutations are frequent in tumors and correlate with chemo/radioresistance and poor clinical outcome [153]; however, even if Keap1 missense or nonsense mutations have also been reported [150], in melanoma, Keap1 and Nrf2 mutations are not frequent. Here, KEAP1 is linked to melanoma.